Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, Thuresson M, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. Among authors: norhammar a. Diabetes Obes Metab. 2018 Aug;20(8):1983-1987. doi: 10.1111/dom.13299. Epub 2018 Apr 17. Diabetes Obes Metab. 2018. PMID: 29569378 Free PMC article.
Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A. Ritsinger V, et al. Among authors: norhammar a. Lancet Diabetes Endocrinol. 2014 Aug;2(8):627-33. doi: 10.1016/S2213-8587(14)70088-9. Epub 2014 May 13. Lancet Diabetes Endocrinol. 2014. PMID: 24831989 Clinical Trial.
Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort.
Ritsinger V, Tanoglidi E, Malmberg K, Näsman P, Rydén L, Tenerz Å, Norhammar A. Ritsinger V, et al. Among authors: norhammar a. Diab Vasc Dis Res. 2015 Jan;12(1):23-32. doi: 10.1177/1479164114551746. Epub 2014 Oct 13. Diab Vasc Dis Res. 2015. PMID: 25311248 Free article.
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Nyström T, et al. Among authors: norhammar a. Diabetes Res Clin Pract. 2017 Jan;123:199-208. doi: 10.1016/j.diabres.2016.12.004. Epub 2016 Dec 19. Diabetes Res Clin Pract. 2017. PMID: 28056431 Free article.
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Nyström T, et al. Among authors: norhammar a. Diabetes Obes Metab. 2017 Jun;19(6):831-841. doi: 10.1111/dom.12889. Epub 2017 Mar 16. Diabetes Obes Metab. 2017. PMID: 28116795 Free PMC article.
133 results